Panels

return to panel list

Realizing CER’s Potential in the United States: Promoting Value while Encouraging Innovation

Given Given rising health care costs and uncertainty around what works in health care, Comparative Effectiveness Research (CER) is emerging as a potential solution to define and promote value in the United States. Proposed legislation to establish a centralized CER entity has implications for many health care stakeholders, including both public and private payers, the medical technology industry, providers, and patients. This panel will examine: 1) The state of the current policy debate around CER and the creation of a centralized entity in the U.S., 2) The challenges and implications a CER entity would place on innovation in health care technology, and 3) How research and information will be disseminated to providers and translated into practice, and the related implications for patients.

 

Moderator & Panelist Bios

Moderator: James Robinson, PhD
Mr. Robinson is the Kaiser Permanente Professor of Health Economics and Director of the Berkeley Center for Health Technology. Dr. Robinson also leads the project on value-based medical device purchasing at the Integrated Healthcare Association.
   

Panelist: Jed Weissberg, MD
Senior VP, Quality and Care Delivery Excellence at Kaiser Permanente

Dr. Weissberg partners with the Permanente Medical Groups, Kaiser Foundation Hospitals, and regional and national leaders to oversee Kaiser Permanente’s national quality agenda, ensuring members and patients receive high-quality care and service.
   

Panelist: Brian O'Shea
Mr. O'Shea works for Genentech, Inc. in Global Health Economics and Pricing, in the role of International Payer Strategy Leader in BioOncology. In that capacity, he works with the teams in BioOncology product development to provide global marketplace insights and forecasts to ensure successful future launches for these therapies.  Prior to his global role, Brian led the Reimbursement Strategy Team in Genentech's Managed Care and Customer Operations group, working closely with the commercial organization and with Genentech's US Government Affairs on several key issues and initiatives, including Comparitive Effectiveness.

Before joining Genentech Brian had nearly 20 years of biopharma experience with GlaxoSmithKline and Astra Merck, working in field sales, strategic contracting and pricing, business planning, managed care segment leadership and US government strategy.  He received his BA from California State University, Fullerton and his MS in International Business from St. Mary's College.  He resides in Orinda with his wife Liz and daughters Anne and Madeline.